- Home
- IPA
as 01-17-2025 4:00pm EST
ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.
| Founded: | 1983 | Country: | Canada |
| Employees: | N/A | City: | N/A |
| Market Cap: | 15.3M | IPO Year: | 2017 |
| Target Price: | $5.00 | AVG Volume (30 days): | 422.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.33 - $2.60 | Next Earning Date: | 03-13-2025 |
| Revenue: | $17,272,336 | Revenue Growth: | 6.36% |
| Revenue Growth (this year): | 1.88% | Revenue Growth (next year): | 9.90% |
Latest ImmunoPrecise Antibodies Ltd. News
IPA Breaking Stock News: Dive into IPA Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation
TipRanks
17 days ago
ImmunoPrecise Antibodies announces resignation of CFO
Business Wire
18 days ago
IPA Announces Resignation of Chief Financial Officer
Business Wire
a month ago
ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases
ACCESSWIRE
a month ago
IPA to Present at The Microcap Conference 2025
Business Wire
a month ago
IPA to Present at The Microcap Conference 2025
Simply Wall St.
a month ago
ImmunoPrecise Antibodies Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Business Wire
a month ago
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025
Compare IPA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IPA ImmunoPrecise Antibodies Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.